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Summary Current cancer chemotherapy regimens may involve 20-30 or more independent variables, each
affecting therapeutic response and toxicity. With standard response surface modelling methods, finding the
optimum combination with as few as 10 variables entails testing over 1,000 combinations, so these methods do
not provide a feasible approach to such problems. However, they may be tackled by direct search methods
(DSM), i.e. stepwise searches of the response surface. Experiments were carried out in advanced L1210
leukaemia treated with combinations of adriamycin with cyclophosphamide, isophosphamide with acetyl-
cysteine and methotrexate with leucovorin. Two established DSM (Nelder-Mead and Box) were used, and a
new method was designed to find consistent search paths in spite of wide biological variation. With
methotrexate and leucovorin, DSM located combinations prolonging mean survival to 40-50 days (compared
with 10.4 in controls) and giving high proportions of long-term survivors. These results were achieved with
single injections of drugs given 7 days after injection of 106 leukaemic cells, i.e. 2-3 days before deaths began
in untreated mice, and appear to be unprecedented with these agents. Searching for optimal combinations of
established agents may be at least as rewarding as searching for new agents, and thus DSM may prove a
powerful tool for improving the results of combination cancer chemotherapy.
Widely used cancer chemotherapy regimens may involve con-
current use of four to six or more agents and for each agent
dose, number of doses and interval between doses may be
independently varied. Furthermore, agents are commonly
given in courses of defined length, and their length, number
and the intervals between them may also be varied. Thus, up
to six variables may be associated with each agent, so that a
regimen of four to six agents may involve at least 20-30
variables, all of which may influence therapeutic and toxic
effects.
The difficulty of finding the optimum combination of
20-30 variables becomes obvious when it is considered that
when responses are not linear (and biological responses are
usually not) each variable must be tested at at least three
levels to determine its relation to response, and a full fac-
torial design for a regimen of 20 variables would thus entail
testing at least 320 combinations. Investigators can hardly be
blamed for avoiding such problems. However, the same con-
siderations show that any complex drug regimen now in use
is exceedingly unlikely to be optimal for that set of drugs;
indeed it may be far from optimal, and there is therefore an
unknown and possibly large gain to be made by searching
for better combinations of the same set. This gain may in
some cases be at least as great as that to be made by
introducing a new agent.
There are two approaches to such problems, i.e. response
surface modelling methods and direct search methods
(DSM). In the former procedure, a predetermined number of
combinations of predetermined composition is examined and
the results fitted by an algebraic expression, usually a second-
order polynomial, the maximum of which is found by stan-
dard mathematical methods. In DSM, after an initial set of
combinations is tested, the response surface is searched one
step (i.e. one combination) at a time, the location of each
successive combination being determined by the results
obtained with previous combinations. The main difficulty
with response surface modelling is that the number of com-
binations that must be tested in order to fit a second-order
function rises more or less exponentially with the number of
variables. For example, the economical central composite
design of Box and Wilson (1951) entails testing 2n + 2n + 1
combinations for a problem in n variables. For a 10-variable
problem, this means testing over 1,000 combinations. It is
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difficult to see how such procedures could be useful in the
multiv'ariate problems posed clinically.
A practical DSM procedure seems first to have been sug-
gested by Spendley et al. (1962). Suppose we wish to find the
best combination of agents A and B, varying doses only. In
Figure I the axes represent drug doses and the contours
represent the response surface (therapeutic effect). At the
outset, no information is available about the shape of the
response surface. First, we compare the effects of three arbit-
rarily chosen combinations (labelled 1, 2 and 3) which form
the vertices of an equilateral triangle (i.e. a regular simplex in
two dimensions). Combination I is found to have the least
effect, so it is discarded and the triangle is reflected about the
axis 2-3 to give combination 4 and a new triangle. Combina-
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Figure 1 Direct stepwise search of a response with combinations
ofdrugs A and B (method of Spendley et al., 1962). The contours
represent levels of effect, and rise to a peak in the region of
7 8mg kg-' A with 5-6 mg kg- B. Initially, combinations 1, 2
and 3 are tested, which form the vertices of an equilateral trian-
gle. Combination I has the least effect, so the triangle is reflected
about axis 2-3 to give a new combination 4 and a new triangle.
Combination 2 is the least effective here, and the next reflection
gives combination 5. With successive reflections, the triangles
climb the response-surface, turning with the contours, until the
optimum is reached with combinations 14 and 15.
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tion 2 is the least effective in this triangle so it is discarded in
turn and the triangle reflected to give combination 5. Thus,
successive moves climb the therapeutic response-surface until
the region of the optimum is reached with combinations 14
and 15. To use this procedure for n variables, a regular
simplex with n + 1 vertices is used instead of a triangle (for
example, if n = 3, the simplex is a tetrahedron).
Nelder and Mead (1964) modified this method to enable
the simplex to expand or contract whenever its movement
was favourable or unfavourable, and Box (1965) further
improved it by increasing the number of vertices (creating
what was called a 'complex') and by incorporating rules
enabling the complex to retreat when it violated a predeter-
mined limit or constraint. In the context of drug treatment,
such constraints could include specified levels of toxicity. The
Nelder-Mead method does not include an explicit rule for
dealing with constraints, but it may be adapted for doing so
by treating a violating combination as if it were the least
effective combination in the simplex.
Direct search methods have been used successfully in
industry and mathematics for many years, but the possibility
that they might be useful in exploring combination cancer
chemotherapy has so far been examined only in computer
simulations (Segreti & Carter, 1979; Segreti et al., 1981). The
work reported here appears to be the first attempt to examine
this possibility in practice.
Initially, the Nelder-Mead and Box methods were studied
in computer simulations, using mathematically formulated
problems with known solutions and artificially induced error,
and it rapidly became clear that they coped poorly if at all
with error of the magnitude typical of biological experiments.
Both methods depend on identifying the least effective com-
bination in the current set and, when error is high, there is a
high probability that the wrong combination will be selected,
and this acts in effect like a misleading signpost pointing in
the wrong direction.
Furthermore, although both procedures incorporate rules
enabling the search to escape from an unacceptably toxic
region, neither is particularly efficient at this. The rules pre-
scribe a partial reversal of the step that led into the toxic
region. When the therapeutic and toxic response surfaces are
not parallel (and they usually are not), many such reversals
may be required before the non-toxic region is re-entered
(Figure 10); in a clinical context, this repeated testing of toxic
combinations would be a serious disadvantage.
Accordingly, these methods were modified in an attempt to
overcome these drawbacks, and a new method, here called
the partition method, was evolved as described below.
Materials and methods
Mice
BDF, (C57B1 x DBA/2) female mice weighing 17-21 g were
obtained weekly from Olac Ltd, and were given food and
water ad libitum.
Leukaemia
The L1210 leukaemia, obtained from the Chester Beatty
Research Institute, was passaged weekly as an ascites tumour
by injection of 106 cells intraperitoneally. For therapeutic
tests, 106 cells, suspended in phosphate-buffered saline,
pH 7.4, were injected subcutaneously. This produced a small
local tumour and a systemic disease that caused death in
about 9-13 days (Goldin et al., 1958, 1966).
Drugs
Methotrexate sodium and leucovorin were obtained from
Lederle Laboratories, cyclophosphamide and isophos-
phamide from Asta Werke, adriamycin from Farmitalia
Carlo Erba and N-acetyl-L-cysteine from Sigma Laboratories.
Drugs were dissolved in physiological saline within a few
hours of use.
Regimens
Cytotoxic drugs were given in single doses on day 7 after
injection of leukaemic cells. Groups of eight mice were used
for each combination and groups of 10 for untreated
controls. Three drug regimens were used, as follows.
Adriamycin-cyclophosphamide Search AC, two-variable
experiment. Single injections of each drug were given simul-
taneously (i.e. within 1 min of each other) into separate
subcutaneous sites.
Isophosphamide-acetylcysteine-time interval Search IAT, three-
variable experiments. A single injection of isophosphamide was
given subcutaneously on day 7 and a single injection of acetyl-
cysteine was given intraperitoneally at various times before or
after this.
Methotrexate-leucovorin-time interval Searches MLT(a) and
(b), three-variable experiment. A single injection of
methotrexate was given subcutaneously on day 7 and a single
injection of leucovorin subcutaneously at various times
before or after this.
Therapeutic effect
This was defined as mean survival time (MST). Mice surviv-
ing 60 days and showing no gross or microscopic evidence of
leukaemia were classified as long-term survivors and, for the
purpose of calculation, were assigned a survival time of 60
days. Consideration was given to evaluating therapeutic effect
in terms of MSTs of treated animals expressed as fractions of
concurrent control MSTs. However, the standard error of the
mean MST in groups of control mice was only 1.5% of the
mean (see below). With such small variation, it was decided
not to use this correction as it would probably have reduced
the accuracy of the results by allowing random errors in the
controls to affect results for the treated groups (R. Peto,
personal communication).
Toxic effects
These were evaluated in two ways.
Weight loss Each group of mice was weighed daily from
day 7 to day 11 inclusive (i.e. on days 0-4 after drug
injection). The mean daily weight change over that period
was expressed as a fraction of the weight on day 7.
Death due to drug toxicity There was usually little difficulty
in deciding whether a mouse had died of toxicity or of
leukaemia. Untreated mice usually died on about days 9-12
with livers grossly enlarged by leukaemic cell infiltration and
weighing 11-13% or more (rarely less than 10%) of body
weight, as compared with a normal liver weight of
4.53%±0.22% (s.e.m.) (n = 11) of body weight. In histo-
logical sections, leukaemic cells usually occupied at least 75%
of the section area, and mice could survive up to day 10-11
with 80-90% of the liver sectional area occupied by
leukaemic cells. Accordingly, mice were judged to have died
of toxicity rather than leukaemia if they died at or before 60
days with a liver weight less than 6% of body weight. Livers
weighing 6-9% of body weight were examined histologically,
and death was ascribed to toxicity if leukaemic cells occupied
less than 50% of the area of the section.
Search methods
The Nelder-Mead and Box methods are fully described in
the original papers and in textbooks (Nelder & Mead, 1964;
Box, 1965; Beveridge & Schechter, 1970; Box et al., 1969;
Shoup & Mistree, 1987). The partition method is described
fully in the Appendix. Its principal differences from the other
two methods were as follows. (1) The direction of steps up
the therapeutic response surface was along the line joining
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effective sets of combinations in the complex, instead of
along a line that depended on identifying the single least
effective combination. This modification was intended to
have the effect of smoothing out errors due to biological
variability. (2) The direction of movement out of a toxic
region was directly down the toxicity response surface instead
of down the therapeutic surface.
Search parameters
The agents used in each search, the number k of combina-
tions in the complex, the maximum and minimum permitted
moves and the toxicity constraints for these experiments are
summarised in Table I.
Results
The mean MST in 24 groups of 10 control mice inoculated
over the period in which the initial complexes were being set
up was 10.4 ± 0.17 (s.e.m.) days. Deaths began almost
invariably on day 9 or 10 and all mice were usually dead by
days 10- 13.
Adriamycin-cyclophosphamide
Search AC is shown in Figures 2 and 3. The six arbitrarily
chosen combinations in the starting complex increased MST
from 10.4 to 12.6-17.4 days. All three search methods in-
creased the MST to 24-26 days within the first four to six
steps, and there was a further rise to 28 -30 days
(Nelder-Mead and Box methods) or to 32-34 days (parti-
tion method) in eight to 12 steps. There was no further
consistent improvement after this. Only one long-term sur-
vivor was obtained in 15 steps in each of the Nelder-Mead
and partition searches (at step 12 in each case).
With all three methods, several combinations were toxic.
The total toxicity-related deaths in 15 steps (120 mice) were
40 for the Nelder-Mead method, 32 for Box and 19 for the
partition method.
When the search paths were plotted graphically (Figure 3),
all three searches tended to move away from the starting
complex into a region of high doses of both drugs, but there
was a clear difference between the rather erratic courses
produced by the Nelder-Mead and Box methods and the
more consistent course of the partition method.
Overall, the partition method caused fewer deaths from
toxicity, had a more consistent search path and produced a
slightly higher MST.
Isophosphamide-acetylcysteine-time interval
Search IAT is shown in Figures 4 and 5. The 10 combina-
tions in the initial complex improved MST to 14-22 days.
All three searches produced MSTs of 30-32 days (in nine
steps with the Nelder-Mead, 11 with the Box and seven with
the partition method), and subsequent moves did not
improve on this. Deaths due to toxicity in 15 steps (120 mice)
Table I Search parameters, showing number k of combinations in
complex, toxicity constraint Tc (fractional weight change), and max-
imum and minimum changes allowed in the variables.
MinimumMaximum
Search k T, Variables change change
AC 6 -0.10 Adriamycin (mgkg') 0.5 2.0
Cyclophosphamide (mg kg ') 20.0 60.0
IAT 10 -0.10 Isophosphamide (mgkg-') 25.0 100.0
Acetylcysteine (mg kg-') 50.0 200.0
Time interval (min) 15.0 No limit
MLT(a) 10 -0.07 Methotrexate (mg kg-') 20.0 80.0
Leucovorin (mgkg-') 10.0 No limit
Time interval (h) 2.0 No limit
MLT(b) 10 -0.05 Methotrexate (mg kg-') 20.0 80.0
Leucovorin (mgkg-') 10.0 No limit
Time interval (h) 2.0 No limit
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Figure 2 Search AC. Mice treated on day 7 with adriamycin and
cyclophosphamide. Stepwise changes in the doses of the two
drugs and in mean survival time (MST) are shown, and also the
yield at each step of toxicity-related deaths (TD) and long-term
survivors (LTS). Numbers of LTS are bracketed. Nelder-Mead
method (NM) - - -, Box method (B) ........ partition method
(P) Starting complex, S. MST of controls 0 (standard
error too small to be shown).
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Figure 3 Search AC showing search paths of Nelder-Mead,
Box and partition methods. Combinations of starting complex
0. Boundaries of starting complex ...... Combinations at steps
1, 5, 10 and 15 are indicated. Note the erratic courses of the
Nelder-Mead and Box methods compared with the more consis-
tent course of the partition method.
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Figure 4 Search IAT. Mice given isophosphamide on day 7.
Stepwise changes in doses of isophosphamide and acetylcysteine
and in time interval, in MST and in the yield of toxicity-related
deaths and long-term survivors are shown. Symbols as in Figure
2.
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Figure 5 Search IAT showing the three search paths. Symbols as
in Figure 3. The drug dose-axes are divided into units of
100 mg kg-' and the time axis into units of 100 min. Note the
much more consistent search path of the partition method com-
pared with the Nelder-Mead and Box methods. Symbols as in
Figure 4.
were for Nelder-Mead, 26 for Box and eight for the
partition method.
The search path produced by the partition method was
considerably more consistent than those produced by the
Nelder-Mead or Box methods. This is clearly shown by the
two dimensional representation in Figure 5 and by plotting
the values of the three variables against step number as in
Figure 4. The Nelder-Mead and Box methods showed some
consistency in the progressive increase in isophosphamide
dose but this consistency was considerably less than that
shown by the smooth rise with the partition method.
Overall, there was little to choose between the three
methods in terms of the maximum MST obtained, but the
partition method achieved this maximum with less cost in
toxicity and with a considerably more consistent search path.
A significant finding was that the partition method pro-
gressively reduced and virtually eliminated acetyclysteine
from the regimen (Figure 4). This prompted an examination
of the effects of isphosphamide on its own, which showed
that this drug in doses of 520-620 mg kg' gave MSTs of
around 30 days, i.e. as good as that given by any combina-
tion of isophosphamide and acetylcysteine used here. It must
be concluded that, in contrast to the results of Kline et al.
(1973) discussed below, acetylcysteine does not improve on
the results obtainable with isophosphamide alone when both
drugs are given on day 7. Figure 4 shows that the steady
reduction in dose of acetylcysteine (steps 1-9) was accom-
panied by a steady rise in MST, suggesting that this agent
may have been positively deleterious in these experiments.
Thus, the partition method not only optimises beneficial
variables but actively eliminates those that are disadvan-
tageous. The Box and Nelder-Mead methods did not do this
in these experiments, probably because their search paths
were too erratic.
Methotrexate-leucovorin-time interval
Search MLT(a) is shown in Figures 6 and 7. The 10 com-
binations in the initial complex gave MSTs of 11.5-15.25
days. The MST fluctuated greatly during all three searches,
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Figure 6 Search MLT(a). Mice given methotrexate on day 7.
Stepwise changes in doses of methotrexate and leucovorin and
time interval, and in the yield of toxicity-related deaths and
long-term survivors are shown. Symbols as in Figure 2. Note the
wide swings in MST due largely to differences in the number of
toxicity-related deaths. Combinations yielding long-term sur-
vivors are usually also toxic. The stepwise changes in methotrex-
ate and leucovorin dosage with the Nelder-Mead and Box
methods appear to be largely random.
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Figure 7 Search MLT(a) showing the three search paths. Sym-
bols as in Figure 3. The drug dose-axes are divided into units of
100 mg kg-' and the time axis into units of I h. The paths of the
Nelder-Mead and Box methods are largely random, whereas
that for the partition method shows moderate consistency.
reaching a maximum of about 50 days (with four to five
long-term survivors per group of eight mice), and minima of
10-12 days with all mice in a group dying of drug toxicity.
The cost in toxicity-related deaths during 15 steps was 24 for
the Nelder-Mead method, 29 for the Box method and 58 for
the partition method. The total of long-term survivors in 15
steps was seven for Nelder-Mead, two for Box and 13 for
the partition method.
The Nelder-Mead and Box methods produced highly
erratic search paths (Figure 7). Indeed, they showed little if
any consistent direction of movement in dosage of
methotrexate or leucovorin. With the partition method,
methotrexate dose showed an early fall and then rose more
or less consistently during the remaining stages of the search.
Thus, with this set of agents, there was no difference
between the methods in achieving prolongation of MST. The
partition method produced more long-term survivors, but at
the cost of greater mortality. However, its search path was
the only one that showed any evidence of consistency.
In search MLT(a), the toxicity constraint was a daily
fractional weight change of -0.07. Subsequently (search
MLT(b)), searches with the Box and partition methods were
repeated, starting from the same initial complex but with the
weight-change constraint set at -0.05 instead of -0.07 in
the hope that this might help the search path to avoid the
toxic region. Again, there was no evident consistency in the
Box search path (Figures 8 and 9) whereas, with the partition
method, there was an early fall in methotrexate dose followed
by a consistent, slow rise. Maximum MSTs were 43 days
with the Box method and 50 days with the partition method.
The Box method produced four long-term survivors at the
cost of eight toxicity-related deaths, while the partition
method produced 14 long-term survivors and 31 deaths.
Thus, as compared with search MLT(a), the number of
toxicity-related deaths was reduced by setting a lower toxicity
constraint, without reducing the yield of long-term survivors.
80'
60'
40'
20'
30'
20'
10-
0.
50-
40-
30-
20'
10
* / -,.
* ' '. '-L
- " \ -----
* N.
,\ --
TD(LT ) f B 2(2) 1 1 3 (1) 1(1)
TD(LTS){p 1(1) (1) (3) 3 5(1) 1 8 2 8 3(1) (4) (3)
STEP S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Figure 8 Search MLT(b) with Box and partition methods. This
search had the same starting complex as search MLT(a) (see
Figure 6), but the toxicity constraint was a daily fractional weight
change of -0.05 instead of -0.07. Note that the yield of long-
term survivors is not affected by this change but the number of
toxicity-related deaths is reduced.
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Figure 9 Search MLT(b) showing Box and partition search
paths. Symbols as in Figure 3. The Box search path is largely
random whereas that for the partition method has moderate
consistency.
Discussion
The principal questions to be asked of an optimum-seeking
method are (a) does it converge on the optimum and (b) how
rapid is the convergence? In simulated (mathematical) prob-
lems, where the optima are known precisely, the search is
judged to have succeeded, and may be stopped, when succes-
sive steps fail to improve the results by more than a specified
amount, or when the known optimum has been approached
to within a specified limit. However, in real, as opposed to
simulated, problems, the position of the optimum is un-
known and so questions about whether it has been reached
and about rapidity of convergence are more difficult to ans-
wer. The only practicable criterion is failure of successive
steps to improve the results, but decisions on this score have
~
/ \ tl-.
//
/ \\ '11\
\v106 M.C. BERENBAUM
E
4-
2-
0 4 8 2
A(mg kg-')
Figure 10 Basic procedures of the partition method (for details,
see text). The contours represent levels of effect which rises with
doses of A and B, but dosage is limited by a toxicity constraint
*l#91111 The complex shown here consists of six combinations
and may be partitioned between three with a higher and three
with a lower effect. L and S are the centroids of these two sets.
N, the next combination in the sequence, lies on the line from
S-L such that the distance N-L is 1.3 times the distance L-S. If
N violates a constraint (as it does here), a move is made down
the slope of the toxicity response surface to find N'. This is
located between W, the combination estimated to have toxicity
equal to the constraint level, and V, the combination estimated to
have toxicity equal to L. If N' does not violate the constraint, it
is accepted in place of the combination with the least effect in the
complex. (In the Nelder-Mead and Box methods, violation by N
is followed by a move half-way back to L).
to take into account the possibly wide fluctuations due to
biological variation.
The searches reported here reached what seemed to be
their optima in seven to 10 steps (in fact, the searches of
MLT(b) did so in two to three steps), for no material imp-
rovement was obtained in several succeeding steps. However,
guidelines for stopping such searches cannot be formulated
without further extensive experience in biological experi-
ments, and will be determined not only by the results of the
searches but also by considerations of time and expense.
It is at least theoretically possible that a response surface
may have more than one peak, so that a search might end on
a minor peak (Beveridge & Schechter, 1970). This possibility
may be investigated by performing two or more searches
with differently located starting complexes. However, the
problem may be unimportant in the present context, for
adequately characterised biological response surfaces have so
far all shown single optima (Carter et al., 1977, 1982, 1985;
Gennings et al., 1988; Solana et al., 1986; Stablein et al.,
1980; Staniswalis & McCrady, 1988; Wampler et al., 1978;
Wilson et al., 1986).
Another difficulty in evaluating search methods is that
combinations chosen at random will occasionally lie in the
therapeutically optimal region. Thus a search method cannot
be evaluated simply by whether or not it ever locates
favorable combinations. For instance, in searches MLT(a)
and (b), there was no evidence of any consistent direction of
search with the Nelder-Mead or Box methods, yet these
searches found some combinations that yielded long-term
survivors. (Six such combinations were found in a total of 45
steps with both methods in both searches, compared with 13
combinations in 30 steps with the partition method.) It
appears, therefore, that the criteria for a good search method
are not only that a therapeutically optimal region should be
found, and found rapidly, but that it should be found by a
more or less consistent search path (i.e. one significantly
different from a random path). In this respect, the partition
method is clearly superior to the other two methods (at least
in these two- and three-variable cases).
The importance of path consistency is two-fold: (1) other
things (e.g. step size) being equal, a consistent path to the
optimum is likely to find it in fewer steps than a more or less
random path; and (2) in a clinical context, a sequence of
combinations that entails systematic trends in dosage and
that produces a more or less consistent improvement in
therapeutic effect is much more likely to be pursued to a
conclusion than one in which doses and effects change
erratically at each step.
This work was done in inbred mice bearing a transplanted
neoplasm of uniform behaviour and drug sensitivity. In con-
trast, human tumours are highly heterogeneous in these
respects. It might therefore be supposed that this
heterogeneity would broaden the optimum region so much
that any arbitrarily chosen regimen would have a high pro-
bability of lying within it. Then, searching the response sur-
face for better regimens might be unrewarding. However, this
situation is unlikely with multivariate regimens. If, say, the
optimum region for each variable was so broad as to cover
half the feasible range, the probability that a randomly
chosen combination of n variables would lie in the optimum
region would be 0.5s. For a 10-variable combination, this
probability would be less than 0.1%.
The results of these searches should be compared with
those reported in the literature for combinations of the same
agents, with the proviso that the effects of chemotherapy on
L1210 leukaemia depend greatly on inoculum size and the
interval between inoculation and treatment.
Combinations of adriamycin and cyclophosphamide have
been reported to be highly effective in L1210 leukaemia.
Treatment 4 days after inocula of 105 cells or 1 day after 106
cells yields many long-term survivors (Tobias et al., 1975;
Avery & Roberts, 1977; Scheving et al., 1980). However,
treatment on day 6 or 8 after giving 105 cells merely in-
creased MST from 11 to 23-24 days, compared with the
32-34 days found here with treatment 7 days after 106 cells.
Little work appears to have been done on the effects of
combinations of isophosphamide and acetylcysteine on
L1210 leukaemia. The experiments reported here were
prompted by the observation of Kline et al. (1973) that a
high proportion of long-term survivors could be obtained.
However, this was with drugs given 24 h after an inoculum of
106 cells. No experiments on effects on late L1210 leukaemia
seem to have been reported.
Comparision with previously reported results is most
revealing in the case of combinations of methotrexate and
leucovorin, for previous relevant work has been fairly comp-
rehensive. Goldin et al. (1966) were able to produce long-
term survivors only by treating mice on day 3 of the disease,
when the body burden of leukaemic cells is about 1% of that
on day 7 (Skipper et al., 1964), and only after an inoculum of
2 x 104 cells (i.e. 2% of that used here). No long-term
survivors were obtained with inocula of 2 x 105 cells or more.
Nixon and Wilson (1983) obtained long-term survivors with
inocula of 105 cells, but treatment was given 53 h after
tumour inoculation. Sirotnak et al. (1978), who gave a single
dose of methotrexate 24 h after 106 leukaemic cells, and
leucovorin 16 h after this, obtained at best rather less than a
doubling of MST. Again, long-term survivors could be
obtained only when 103 cells or less were inoculated. The
results obtained here therefore seem to be unprecedented and
underline the suggestion made at the outset of the paper, that
searching for optima with established sets of agents may be
highly rewarding.
In the searches with methotrexate and leucovorin combina-
tions, it seemed impossible to avoid toxicity-related deaths.
Of the 19 combinations in all five searches that yielded
long-term survivors, 13 also produced toxicity-related deaths.
Similarly, Sirotnak et al. (1978) found that, of 47 combina-
tions of these drugs that increased MST in animals with
L1210 leukaemia (106 cells) or Sarcoma 180 by 50% or more,
39 also caused deaths from toxicity. These findings suggest
that, with this set of agents, the regions of high therapeutic
effect and of high toxicity overlap or are very close, and
therefore that, even when the search path is consistent,OPTIMISATION OF CANCER CHEMOTHERAPY REGIMENS 107
improvements in survival may be erratic, as illustrated by the
marked swings from high to low survival times seen in
Figures 6 and 8.
The version of the partition method described here must be
regarded as no more than a first attempt at the problem of
devising a search method that takes adequate account of
biological variation and the need to avoid undue toxicity.
Improvements are clearly required, for instance, the follow-
ing.
The rules for dealing with toxicity (see Appendix), while
effective in reducing toxicity-related deaths, require the deter-
mination of a multilinear regression for toxicity in the presence
of marked biological variability, a procedure fraught with
pitfalls. In principle, the direction of movement for reducing
toxicity could be determined in the same way as the direction
for increasing therapeutic effect, i.e. by partitioning the com-
plex into sets of combinations of greater and lesser toxicity
and moving along the vectorjoining the centroids of these sets.
This would greatly simplify computation. Other rules that,
with the benefit of hindsight, clearly require modification or
elimination are the rule for a half-way retreat and the min-max
rule. The former was simply taken over from the
Nelder-Mead and Box methods. In the present context it is
inappropriate as it implicitly assumes that the therapeutic and
toxicity response surfaces are parallel. When they are not,
attempts to leave the toxic region are often ineffective. The
min-max rule often failed in its aim of preventing moves that
were too small. The mistake here was to set the minimum
distance of move from the centroid of the best set ofcombina-
tions, whereas it would have been better to set this distance
from the preceding combination in the sequence.
Several problems require investigation, as follows.
1. If a search has reached an apparent optimum, as shown
by failure of results to improve in further steps, this may be
because: (a) the true optimum has been reached or (b) the
optimum has not been reached but the search has lost its way
because of large intrinsic error in the measurements or
because of a defect in the method. The possibility that the
true optimum has been reached might be confirmed by
repeating the search from a different starting location. If the
first search has indeed located the true optimum, the second
should converge on the same region.
2. The effect of varying the number of combinations in the
complex requires investigation. The greater the number of
combinations, the greater the ability of the search to override
the effects of experimental error and so the more consistent
the search path, but the steps will be smaller and progress
over the response surface slower.
3. Other parameters requiring systematic investigations are
the orientation of the starting complex and the magnitude of
the reflection factor a.
In spite of these defects and problems, the great advan-
tages and the potential of direct search methods are clear.
1. They involve one step at a time, and only one new
combination is investigated at each step so that they are
highly economical.
2. These methods appear to be the only practicable way to
handle problems with the numerous variables typical of
clinical regimens. Although the searches described here were
limited to two- and three-variable problems, this restriction
was imposed because, at this early stage in the development
of the methods, it was felt essential to be able to visualise the
search path in order to assess its performance, analyse
problems as they arose and devise modifications. A search
involving more variables would differ in that the number of
combinations in the starting complex would be greater (it
must exceed the number of variables), and path consistency
could not be assessed visually (although it could be assessed
by considering the stepwise changes in each variable
separately, as in Figures 2, 4, 6 and 8). However, after
examination of the starting complex, combinations would
still be tested one at a time. There is no reason to suppose that the difficulty of direct searches is substantially dependent
on the number of variables, and it is relevant that Spendley
et al. (1962) found that the efficiency of their method actually
increased with the number of variables (tested up to n = 5 in
a simulated experiment). However, this question clearly needs
investigation with any proposed new method, in both
simulated and real problems.
3. They involve no assumptions about the shape of the
response-surface, and therefore avoid the problems that arise
from the inevitable divergence between the real surface and any
that may be fitted by algebraic methods (Berenbaum, 1990).
4. Unlike conventional clinical trials, which usually
demand large numbers of subjects so as to achieve statistical
significance in comparing any two regimens, there is no need
for the differences between the effects of any two successive
combinations in a sequence to be statistically significant
(most of the differences in MST between successive steps in
searches AC and IAT are clearly insignificant) as it is the
overall trend that is important. In fact, Spendley et al. (1962)
found that replicating observations in order to reduce error
was a positively counter-productive allocation of resources.
Consequently, searches are carried out most efficiently with
small numbers per group. (The position is similar to that in
response surface modelling, where as few as two animals per
group have been used (Wampler et al., 1978).) This raises the
possibility of carrying out many different searches simul-
taneously without using more resources than may be needed
for a much smaller number of large-scale conventional trials.
Searches showing early promise could be pursued and the
rest aborted and new searches initiated in their place. Thus a
marked adaptability to changing circumstances and the
opportunity to exploit advantages rapidly are provided which
are not available in conventional trials, with their fixed com-
mitments.
5. An outstanding advantage of DSM is their flexibility.
Additional variables (e.g. extra drugs) may be added during
the search and, to a large extent, it is even possible to change
the rules of the search after it has begun. For instance, the
number of combinations in the complex could be increased,
the sample size per combination changed and the reflection
factor and toxicity constraint(s) altered with little difficulty.
This flexibility makes DSM an attractive proposition for
clinical trials. A stepwise search to optimise the variables in a
clinical problem may take a considerable time, during which
pressure to change the rules or add new drugs may become
irresistible. The ability to accommodate such changes if the
need arises must be an important consideration in deciding
whether to embark on such searches.
The most obvious drawback of DSM is their sequential
nature. Although there are many conditions in which the
effects of a combination may be assessed within weeks or
even days, cancer is not one of them. Testing, say, a dozen or
more combinations in sequence when each assessment may
take many months is a daunting prospect, even when the
result may be greatly improved therapy. However, there are
some mitigating circumstances. For instance, advantageous
combinations found early in a search (see Figures 6 and 8)
may be selected for more comprehensive testing and possibly
adopted for clinical use while the search continues. Again,
the next move in a sequence is determined as soon as the
current complex can be partitioned into the better and worse
sets, and this may be effected long before final results have
been obtained for the best combinations.
Nevertheless, the problems raised by the duration of step-
wise searches are serious, possibly no less serious than those
raised by large-scale conventional trials. In both cases, the
possible therapeutic gains have to be weighed against cost in
terms of resources and organizational difficulty.
Appendix
Initial complex
For a problem in n variables, an n-dimensional complex is
created, consisting ofk combinations, where k>n + 1. Com-
binations are selected so that each variable extends over a
useful range (e.g. for drugs in animals, from near zero to a108 M.C. BERENBAUM
dose somewhat below the minimum lethal dose). The thera-
peutic and toxic effects of all combinations in the starting
complex are measured, and any found to violate a specified
toxicity constraint are replaced by new combinations which
are tested in turn until the number of non-violating combina-
tions required for the complex is obtained.
Partitioning
The k combinations in the initial acceptable complex are
ranked according to length of MST produced. Thus the
complex may be written in vector notation as (cl, C2, C3,
... ,Ck2, Ck), C) where cl is the combination giving the longest
survival time and Ck that which gives the shortest. The com-
plex is then partitioned into two equal sets (if k is even),
consisting respectively of those giving the longer and those
giving the shorter MSTs. The centroids L and S of these two
sets are calculated. These are
L = 2/k (cl + C2 + * * *Ck/2)
S = s/k (Ck,2 +I... + Ck-l + Ck), where the usual rules
of vector addition and multiplication by a scalar hold. If k is
odd, the partition may be made between the best ((k/2)- 1)
and the worst ((k/2) + 1) combinations.
If the same MST is given by more than one combination
in a complex, ranking is on the basis of survival calculated
by life-table analysis (Peto et al., 1977).
Construction ofa new combination
A new combination N is generated by the equation
N =(a+ I)L-aS
where a>0. Box (1965) recommends a= 1.3, and that value
has been used here. The move to N is along the vector
joining S to L, the distance between N and L being a times
the distance between S and L. If the calculation assigns a
negative value to the dose of a drug, the dose is set at zero,
and this value is used in subsequent calculations. A negative
value for time-interval creates no difficulties for it entails
merely reversing the order of administration of the drugs.
Accordingly, the calculated negative value is used in subse-
quent calculations.
Acceptance ofthe new combination
If the therapeutic effect of the new combination N is not less
than that of Ck-I and if it does not violate a constraint, it is
added to the complex and the least effective combination Ck is
discarded. Thus, a new complex is formed in which the
combinations are re-ordered and partitioned in turn as
above.
Rejection ofthe new combination
Retreat If the MST of N is less than that of CkI1, it is
presumed that the search path has overshot the optimum and
a step back is made by constructing a new combination half
way between N and L (i.e. it is 0.5(N + L)), and this com-
bination is examined for partitioning.
Constraint violation: Orthogonal move out of the toxic
region If N violates a toxicity constraint, an attempt is
made to approximate the toxicity response-surface by a linear
surface or hypersurface and to move down this at right-
angles (orthogonally) to its level contours to a region of less
toxicity, as follows.
A multilinear regression is calculated for the toxicity levels
for all the combinations in the complex except the one that
was last discarded. Toxicity T is given by
n
T = Po + E ixi
where xi is the value of the ith variable (i = (1,2,...,n). Then,
two points V and W are located, both on the vector
orthogonal to the surface described by the linear toxicity
regression, such that Tv (toxicity at V) equals that at L (the
centroid of the set of best combination in the complex) and
Tw equals the specified toxicity constraint Tc (Figure 10).
The values of the variables in V are given by
XiV = XiN - ii pi
n
IIPiTi
where A =
n
E pi2
i= I
and y, = XiN - XiL
The values of the variables in W are given by
Xiw = XiN - i TN - TC where it = n
l = I
The new point N' lies between V and W. When the
therapeutic and toxicity response surfaces are parallel or
nearly so, it is desirable to place N' far from the constraint,
otherwise the next step is likely to violate the constraint
again, so it is placed near V. When the surfaces are
orthogonal or nearly so, this risk is less, so N' is placed near
W, so as to maximise the therapeutic response. N' is placed
by calculating the angle 0 between the vector for L and N
and that from N to V and W (Figure 10). This is given by
n
cos 0 = i='
n
E p2 E j2
Then N' = cos 0 | V + (1- cosO W
Repeated constraint violation If an orthogonal move for
constraint violation results in a new combination that also
violates a constraint, the move is repeated, the required
parameters for the calculation being derived from the com-
plex in which the latest violating combination temporarily
replaces the combination with the lowest MST in the current
complex. Once a non-violating combination is found, the
temporarily replaced combinations are restored and the toxic
combinations discarded.
Min-max rule
This rule is intended to avoid moves being too small (which
slows the search), or too large (incurring the risk of a deep
incursion of the toxic region). It is applied to each of the
above moves and limits their size without altering their direc-
tion, as follows.
Let di and Di be respectively the minimum and maximum
changes permitted in the ith variable (see Table I). Calculate
for each variable
dand F. = Di where YiN = X,N-XiL as above.
Let f be the least f and F the greatest Fi.
There are then three possibilities for each proposed move
from L to N.
(a) All f< 1, in which case the move is lengthened to N'
where 1
N' = L + (N- L)
(b) One or more Fi> 1, in which case the move is shortened
to N' where I
N' = L +-(N - L)
(c) Neither (a) nor (b) holds, in which case N is acceptable.
I am grateful to the Cancer Research Campaign for supporting this
work, to Anne Goldsmith and William Russell for technical
assistance, to Richard Peto for statistical advice, to Peter Johnson
for writing computer programs and to Asta Werke, Farmitalia Carlo
Erba and Lederle Laboratories for gifts of drugs.OPTIMISATION OF CANCER CHEMOTHERAPY REGIMENS 109
References
AVERY, T.L.&ROBERTS, D.(1977). Adriamycin andcyclophosphamide
in combination chemotherapy ofL1210 leukemia. Cancer Res., 37,
678.
BERENBAUM, M.C. (1990). What is synergy? Pharmacol. Rev. (in the
press).
BEVERIDGE, G.S.G. & SCHECHTER, R.S. (1970). Optimization: Theory
and Practice. McGraw-Hill Kogakusha: Tokyo.
BOX, M.J. (1965). A new method of constrained optimization and a
comparison with other methods. Computer J., 8, 42.
BOX,M.J., DAVIES, D.&SWANN,W.H. (1969). Non-LinearOptimization
Techniques. Oliver & Boyd: Edinburgh.
BOX, G.E.P. & WILSON, K.B. (1951). On the experimental attainment of
optimum conditions. J. R. Stat. Soc. B., 13, 1.
CARTER, W.H.Jr, JONES, D.E. & CARCHMAN, R.A. (1985). Application
of response surface methods for evaluating the interactions of
soman, atropine, and pralidioxime chloride. Fundament. Appl.
Toxicol., 5, S232.
CARTER, W.H.Jr, WAMPLER, G.L., CREWS, S.L. & HOWELLS, R. (1977).
Ondetermining thelevelsoftreatment to optimize theprobability of
a favorable response. Cancer Treat. Rep., 61, 849.
CARTER, W.H.Jr, WAMPLER, G.L., STABLEIN, D.M. &CAMPBELL, E.D.
(1982). Drugactivity and therapeutic synergism in cancer treatment.
Cancer Res., 42, 2963.
GENNINGS, C., CARCHMAN, R.A., CARTER, W.H.Jr & 6 others (1988).
Assessing physostigmine efficacy by response surface modelling: a
comparision to pyridostigmine efficacy. J. Am. Coll. Toxicol., 7,
1013.
GOLDIN, A., VENDITTI, J.M., HUMPHREYS, S.R. & MANTEL, N. (1958).
Quantitative evaluation of chemotherapeutic agents against
advanced leukemia in mice. J. Natl Cancer Inst., 21, 495.
GOLDIN, A., VENDITTI, J.M., KLINE, I. & MANTEL, N. (1966). Eradica-
tion of leukaemic cells (L1210) by methotrexate and methotrexate
plus citrovorum factor. Nature, 212, 1548.
KLINE, I., GANG, M., WOODMAN, R.J., CYSYK, R.L. & VENDITTI, J.M.
(1973). Protection with N-acetyl-L-cysteine (NSC- 111180) against
isophosphamide (NSC-109724) toxicity and enhancement of
therapeutic effect in early murine L1210 leukemia. Cancer
Chemother. Rep., 57, 299.
NELDER, J.A. & MEAD, R. (1964). A simplex method for function
minimization. Computer J., 7, 308.
NIXON, P.F. & WILSON, L. (1983). Identical efficacy of methotrexate
regimens with N5-methyltetrahydrofolate rescue or with leucovorin
rescue for treatment ofL1210 murine leukemia. Cancer Treat. Rep.,
67, 59.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others (1977). Design and
analysis of randomized clinical trials requiring prolonged observa-
tion ofeach patient. II. Analysis and examples. Br. J. Cancer, 35, 1.
SCHEVING, L.E., BURNS, E.R., PAULY, J.E. & HALBERG, F. (1980).
Circadian bioperiodic response of mice bearing advanced L1210
leukemia to combination therapy with adriamycin and cyclophos-
phamide. Cancer Res., 40, 151 1.
SEGRETI, A.C. & CARTER, W.H.Jr (1979). Monte Carlo evaluation of
several sequential optimization techniqueswhen the responseistime
to an event. J. Stat. Comput. Simul., 9, 289.
SEGRETI, A.C., CARTER, W.H.Jr & WAMPLER, G.L. (1981). A Monte
Carloevaluation oftherobustnessofseveralsequentialoptimization
techniques when the response is time to an event. J. Stat. Comput.
Simul., 12, 209.
SHOUP, T.E. & MISTREE, F. (1987). Optimization Methods. Prentice-
Hall: Englewood Cliffs, NJ.
SIROTNAK, F.M., MOCCIO, D.M. &DORICK, D.M. (1978). Optimization
ofhigh-dose methotrexate with leucovorin rescue therapy in L1210
leukemia and Sarcoma 180 murine tumor models. Cancer Res., 38,
345.
SKIPPER, H.E., SCHABEL, F.M.Jr &WILCOX, W.S. (1964). Experimental
evaluation ofpotential anticancer agents. XIII. On the criteria and
kinetics associated with 'curability' of experimental leukemia.
Cancer Chemother. Rep., 35, 1.
SOLANA, R.P., CHINCHILLI, V.M., WILSON, J., CARTER, W.H.Jr &
CARCHMAN, R.A. (1986). Estimation and analysis of the
concentration-response surfaces associated with multiple agent
combinations. Toxicol. Appl. Pharmacol., 85, 231.
SPENDLEY, W., HEXT, G.R. & HIMSWORTH, F.R. (1962). Sequential
application of simplex designs in optimisation and evolutionary
operation. Technometrics, 4, 441.
STABLEIN, D.M., CARTER, W.H.Jr & WAMPLER, G.L. (1980). Survival
analysis of drug combinations using a hazards model with time-
dependent covariates. Biometrics, 36, 537.
STANISWALIS, J.G. & MCCRADY, C.W. (1988). The use of kernel
estimators in describing human T lymphocyte proliferation induced
by phorbol estersandCa2+ionophore. J. Am. Coll. Toxicol., 7,939.
TOBIAS,J.S., PARKER, L.M.,TATTERSALL, M.H.N. &FREI, E. III(I1975).
Adriamycin/cyclophosphamide and adriamycin/melphalan in
advanced L1210 leukaemia. Br. J. Cancer, 32, 199.
WAMPLER, G.L., CARTER, W.H.Jr&WILLIAMS, V.R. (1978). Combina-
tion chemotherapy: arriving at optimal treatment levels by incor-
porating side effect constraints. Cancer Treat. Rep., 62, 333.
WILSON, J.D., CARTER, W.H.Jr, CAMPBELL, E.D., KESSLER, F.K. &
CARCHMAN, R.A. (1986). Application of response-surface
methodology to detect interactions ofgenotoxic agents in cultured
mammalian cells. J. Toxicol. Environ. Health, 19, 173.